These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7492077)

  • 21. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.
    Ito T; Matsumoto M; Nishino T
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1522-5. PubMed ID: 7492097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of ciprofloxacin resistance mutations in Campylobacter jejuni gyrA by nonradioisotopic single-strand conformation polymorphism and direct DNA sequencing.
    Charvalos E; Peteinaki E; Spyridaki I; Manetas S; Tselentis Y
    J Clin Lab Anal; 1996; 10(3):129-33. PubMed ID: 8731499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
    Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
    J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H; Kusano N
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
    Ferrero L; Cameron B; Crouzet J
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1554-8. PubMed ID: 7492103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H; Wiedemann B; Heisig P
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
    Ruiz J; Sierra JM; De Anta MT; Vila J
    Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
    Cheng AF; Yew WW; Chan EW; Chin ML; Hui MM; Chan RC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):596-601. PubMed ID: 14742214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
    Muñoz Bellido JL; Alonso Manzanares MA; Yagüe Guirao G; Gutiérrez Zufiaurre MN; Toldos MC; Segovia Hernández M; Garcia-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.
    Weigel LM; Steward CD; Tenover FC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2661-7. PubMed ID: 9756773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.